Title: Compositions and Methods for Short-Interfering Nucleic Acid Inhibition of NAv1.8
Filed: Oct. 26, 2005
Lead Inventor: Sameer Goregaoker, Canji
“The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the NAv1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain,” the patent application’s abstract states.
Title: miR-155 Assay
Filed: Feb. 13, 2006
Lead Inventor: James Dahlberg, University of Wisconsin, Madison
According to the patent application’s abstract, the invention “provides methods for diagnosing B-cell lymphoma in an animal. In particular, the invention provides methods for distinguishing an animal having diffuse large B-cell lymphoma with an activated B-cell phenotype from an animal having DLBCL with a non-activated germinal-center phenotype. The invention also provides methods for identifying compounds for treating B-cell lymphoma,” it adds. “The invention further provides reagents and methods for determining the amount of miR-155 in sample isolated from an animal. In this regard, the invention provides a set of oligonucleotides for determining the amount of miR-155 in sample isolated from an animal.”